Navamedic ASA Annual General Meeting June 8, 2015 Johan Reinsli Chairman of the Board Tom Rönnlund Chief Executive Officer
Navamedic - Generalforsamling 8. juni 2015 1. Åpning av generalforsamlingen ved styrets leder. Fortegnelse over fremmøtte aksjonærer. 2. Valg av møteleder. 3. Valg av en person til å undertegne protokollen sammen med møteleder. 4. Godkjennelse av innkalling og dagsorden. 5. Godkjennelse av årsregnskap for 2014 for Navamedic ASA og konsernet, samt årsberetningen. Styret foreslår at det ikke utbetales utbytte for regnskapsåret 2014. 6. Endring av vedtekter. 7. Fastsettelse av godtgjørelse til styret, revisjonsutvalget og kompensasjonsutvalget for 2015. 8. Behandling av styrets erklæring om fastsettelse av lønn og annen godtgjørelse til ledende ansatte etter allmennaksjeloven 6-16a. 9. Godkjennelse av revisors honorar for 2014. 10. Valg av styremedlemmer. 11. Fastsettelse av godtgjørelse til valgkomiteen for 2015. 12. Valg av medlemmer til valgkomité. 13. Fullmakter til styret til å forhøye aksjekapitalen ved rettede emisjoner. 14. Fullmakt til styret til å forhøye aksjekapitalen i forbindelse med aksjeincentivprogram. Presentasjon av Tom Rönnlund CEO i Navamedic 2
2014 in brief First year with positive net profit Turnover up +47% Gross Margin 24% Operating Cost down 3% - saving of 1,1 m NOK EBITDA growth +71% - increase of 5,5 m NOK EBITDA margin 5,9% 3
Navamedic strategy 1. Focus on prioritized therapeutic segments with attractive margins 2. Geographic focus on Nordic markets 3. Broader sourcing base products and suppliers 4. Non-organic growth through acquisitions A strategy aimed at improving profitability 4
2014 Business Development Activities Mandate from shareholders of up to 30% share issue Task force consisting of Board members and Management Evaluated multiple targets - selection criterias: Within Navamedics financial capabilities Significant sales and profitability potential Acceptable risk profile Positive cash flow within short period of time Evaluated targets to date not meeting selection criterias alternatively unattractive valuations Efforts continuing with full speed and additional resources Recruitment of CEO with Business Development experience 5
New CEO Tom Rönnlund Started May 18, 2015 Experience from Life Science industry: General Management Business Development Management Consulting Sales & Marketing Previously at: IMS Health Bristol Myers-Squibb Eli Lilly & Co 6
Navamedic ASA Present in Nordic & Benelux region Targeted therapeutic area focus to drive synergies Representing and distributing: Rx and OTC pharmaceuticals Medical Nutrition Medical Device and Diagnostics Consumer Healthcare Seven consecutive years with revenue growth Improving profitability Long term partnerships with high quality suppliers Well established pharmacy chain relationships In-house regulatory expertise Lean structure with focus on marketing and sales execution 7
The Nordic region is our core market Nordics represent almost 80 per cent of Navamedic sales Attractive partner in the Nordics: Local resources in all markets Therapeutic area expertise Experienced staff able to handle: Regulatory Pricing Market access Distribution Brand building Sales, Marketing & Customer Service Iceland 1% Norway 13% Benelux 23% Denmark 14% Finland 14% Sweden 35% Significant differences in market structure and purchasing regimes within the Nordic region Requires local understanding and approach 2014 sales Transferring majority of Benelux sales to Aspen in 2015 8
Moving forward Navamedic s business model has successfully generated considerable revenue growth and improved profitability Increased focus on IR & External Communication Focus on execution and driving key priorities! Profitability Product mix OPEX control Decrease risk Strengthen portfolio Supplier contracts Targeted growth Profitable segments Leveraging expertise An even stronger Navamedic Non-organic growth Synergistic or expansive acquisitions and partnerships 9
Navamedic ASA Annual General Meeting June 8, 2015